1-(6-bromo-3-(pyrrolidin-1-yl)pyrazin-2-yl)-4-methyl-1,4-diazepane | 894808-49-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(6-bromo-3-(pyrrolidin-1-yl)pyrazin-2-yl)-4-methyl-1,4-diazepane
• 英文别名: 1-(6-Bromo-3-(pyrrolidin-1-yl)pyrazin-2-yl)-4-methyl-1,4-diazepane；1-(6-bromo-3-pyrrolidin-1-ylpyrazin-2-yl)-4-methyl-1,4-diazepane
• CAS: 894808-49-2
• 化学式: C₁₄H₂₂BrN₅
• 分子量: 340.266
• InChiKey: YYZMWQLBOJYSFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-甲基高哌嗪 、 3,5-Dibromo-2-(pyrrolidin-1-yl)pyrazine 以providing the diaminopyrazine (400 mg, quant) as a brown oil的产率得到1-(6-bromo-3-(pyrrolidin-1-yl)pyrazin-2-yl)-4-methyl-1,4-diazepane
  参考文献：
  名称：

  AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS

  摘要：

  本发明公开了使用氨基吡嗪类似物治疗rho激酶介导的疾病或rho激酶介导的状况的方法，包括控制眼压和治疗青光眼。本发明还公开了用于治疗眼部疾病（如青光眼）和控制眼压的眼科药物组合物，该组合物包括有效量的氨基吡嗪类似物。

  公开号：

  US20080269249A2

文献信息

• Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
  申请人：Hellberg R. Mark

  公开号：US20060142307A1

  公开（公告）日：2006-06-29

  Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.

  使用氨基吡唑类似物治疗rho激酶介导的疾病或rho激酶介导的状况的方法被披露。这些疾病或状况包括控制眼内压和治疗青光眼。还披露了用于治疗眼疾如青光眼以及用于控制眼内压的眼科药物组合物，该组合物包含有效量的氨基吡唑类似物。
• AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS
  申请人：Hellberg Mark

  公开号：US20080269249A2

  公开（公告）日：2008-10-30

  Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.

  本发明公开了使用氨基吡嗪类似物治疗rho激酶介导的疾病或rho激酶介导的状况的方法，包括控制眼压和治疗青光眼。本发明还公开了用于治疗眼部疾病（如青光眼）和控制眼压的眼科药物组合物，该组合物包括有效量的氨基吡嗪类似物。
• AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES
  申请人：Novartis AG

  公开号：EP1830853B1

  公开（公告）日：2011-08-10
• 2,3-Diaminopyrazines as rho kinase inhibitors
  作者：Alan J. Henderson、Mark Hadden、Cheng Guo、Neema Douglas、Helene Decornez、Mark R. Hellberg、Andrew Rusinko、Marsha McLaughlin、Naj Sharif、Colene Drace、Raj Patil

  DOI：10.1016/j.bmcl.2009.12.012

  日期：2010.2

  Inhibition of rho kinase ( ROCK) has been recognized as an important target for a number of diseases, including glaucoma. Herein we report SAR development around two hits from a kinase library that led to the discovery of the ROCK inhibitor compound 38. In vitro and in vivo analysis of this compound, including its effects in a monkey model of glaucoma will be discussed. (C) 2009 Elsevier Ltd. All rights reserved.